Melatonin: Another avenue for treating osteoporosis?

• Published in: Journal of pineal research 2019-03, Vol.66 (2), p.e12548-n/a
• Main Authors: Li, Tian, Jiang, Shuai, Lu, Chenxi, Yang, Wenwen, Yang, Zhi, Hu, Wei, Xin, Zhenlong, Yang, Yang
• Format: Article
• Language: English
• Subjects: age; bone; melatonin; osteoblast; osteoclast; osteoporosis
• ISSN: 0742-3098; 1600-079X
• DOI: 10.1111/jpi.12548

Melatonin is a signal molecule that modulates the biological circadian rhythms of vertebrates. Melatonin deficiency is thought to be associated with several disorders, including insomnia, cancer, and cardiovascular and neurodegenerative diseases. Accumulating evidence has also indicated that melatonin may be involved in the homeostasis of bone metabolism. Age‐related reductions in melatonin are considered to be critical factors in bone loss and osteoporosis with aging. Thus, serum melatonin levels might serve as a biomarker for the early detection and prevention of osteoporosis. Compared to conventional antiosteoporosis medicines, which primarily inhibit bone loss, melatonin both suppresses bone loss and promotes new bone formation. Mechanistically, by activating melatonin receptor 2 (MT2), melatonin upregulates the gene expression of alkaline phosphatase (ALP), bone morphogenetic protein 2 (BMP2), BMP6, osteocalcin, and osteoprotegerin to promote osteogenesis while inhibiting the receptor activator of NF‐kB ligand (RANKL) pathway to suppress osteolysis. In view of the distinct actions of melatonin on bone metabolism, we hypothesize that melatonin may be a novel remedy for the prevention and clinical treatment of osteoporosis.